RIGVIR® is the first approved oncolytic virotherapy. RIGVIR® is approved for the treatment of cutaneous melanoma, local treatment of skin and subcutaneous metastases of melanoma, for prevention of relapse and metastasis after radical surgery.
RIGVIR® is a live, non-pathogenic Picornaviridae genera, Enterovirus genus, ECHO group, type 7 virus that has not been genetically modified.
RIGVIR® has oncolytic and oncotropic properties, it selectively infects tumour cells. Oncolytic virotherapy with RIGVIR® is a safe and effective cancer treatment, which improves time to progression, overall survival and the quality of life for cancer patients. RIGVIR® is well tolerated and causes no if any serious adverse effects.
RIGVIR® is administered intramuscularly.
RIGVIR® should be stored at -20 °C, transported frozen and thawed just before the use.
RIGVIR® was first registered in Latvia in 2004. Currently RIGVIR® is also approved in Georgia, Armenia and Uzbekistan thus ensuring the availability of the medicine with a market of approximately 40 million people. National registration processes have also been launched in other countries.
Since 2011 RIGVIR® is fully reimbursed for residents of Latvia and over 70% of reimbursed melanoma patients have been treated with RIGVIR®. Since 2015 RIGVIR® is included in the national guidelines for melanoma treatment in Latvia.
Both pre-registration and post-registration studies have demonstrated a significant RIGVIR® response to many cancer types besides melanoma, for example stomach and rectum cancer etc. as well as rare diagnoses.